NCT03067467
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Early Phase 1
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 60 Years (Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients with previous or current treatment by radiation or chemotherapy
https://ClinicalTrials.gov/show/NCT03067467